U.S. stock market mid-session update: Fractyl Health down 66.17%, FDA feedback pending, market holds a wait-and-see attitude towards Revita's prospects

U.S. Stock Market Midday Update Fractyl Health fell 66.17%. Based on recent key news: On January 29, Fractyl Health announced the 6-month randomized study data for the Revita treatment, showing that patients maintained good weight after discontinuation of GLP-1, with high safety and reduced appetite. This data attracted market attention, causing significant stock price fluctuations. Source: Reuters On January 29, the company requested FDA feedback on the De Novo pathway for Revita, expecting to receive a response in the second quarter of 2026. This move may affect the product's market access, leading to stock price volatility. Source: Reuters On January 29, Fractyl Health released detailed documents regarding the clinical results and regulatory progress of the Revita endoscopic procedure, emphasizing its commercial readiness. The market remains cautious about its future development, impacting the stock price. Source: Public Technologies The healthcare industry faces regulatory challenges, with significant capital outflows. Top Stocks by Industry Trading Volume Abbott rose 0.43%, with increased trading volume. Based on recent key news: On January 26, Abbott CEO Robert Ford purchased company stock, boosting market confidence. Ford bought over $2 million worth of stock, driving the share price up. On January 27, analysts held an optimistic view on Abbott's long-term prospects, despite short-term pressures in the nutrition and diagnostics businesses. Analysts believe the company performs strongly in high-growth areas, supporting a rebound in stock price. On January 27, Abbott's stock price ended a six-day decline, closing up 1.2%. The previous price pressure was due to weak technical momentum, and the recent rebound indicates improved market sentiment. The medical technology industry has performed strongly recently, with noticeable capital inflows. GlucoTrack fell 3.23%. No significant news recently; trading was active, with clear capital flows. Considering sector and industry trends, the stock showed significant volatility, with specific reasons needing further observation. no_news Intuitive Surgical fell 1.19%. Based on recent key news: On January 28, Intuitive Surgical executives Myriam Curet and Gary S. Guthart sold company common stock, raising market concerns about internal confidence, leading to a drop in stock price. According to disclosures from the EDGAR system, the sale may affect investor sentiment. On January 26, the FDA approved the expanded indications for the da Vinci surgical system for cardiac surgery. Although this news indicates technological advancement, it failed to immediately boost the stock price. This approval expands the application scope of the da Vinci system, demonstrating its safety and effectiveness in cardiac surgery. On January 26, China Merchants Securities initiated coverage on Intuitive Surgical with an "Overweight" rating and a target price of $613. The report highlighted Intuitive Surgical's leading position in the surgical robotics field and its growth potential in surgical volume, but the market reaction was limited The surgical robot industry has significant growth potential and requires attention. Stocks ranked at the top of the industry market value Boston Scientific fell by 1.06%. Based on recent news, On January 28, Boston Scientific was viewed positively in R. Dennis's Substack, where the article summarized an optimistic outlook for the company. Boston Scientific's price-to-earnings ratios are 50.06 and 26.95, indicating market expectations for its future growth. On January 26, EVERCORE included Boston Scientific in its tactical outperform list, which boosted market confidence in the company. On January 27, despite Boston Scientific currently having a moderate buy rating among analysts, top analysts believe there are five stocks that are more worthy of purchase, which may have had a negative impact on its stock price. The healthcare industry is viewed as a strategic core allocation in the current environment, combining stability and growth potential